surmount 3 tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Semaglutide vs. Tirzepatide for Obesity

F.AndreazzaA

Healthcare workers, teachers, or others in demanding professions may prefer evening dosing to avoid managing potential side effects during work hours

An open-label phase 2 trial evaluating the investigational ASK1 inhibitor selonsertib (GS-4997) alone or in combination with the monoclonal antibody simtuzumab (SIM) in NASH patients with moderate-to-severe liver fibrosis (stages 2/3)

Eye examinations check for diabetic retinopathy changes, particularly important during rapid glucose improvement

Fat 0g

Common side effects may include: nausea, vomiting, diarrhea, constipation, bloating, fatigue, stomach discomfort, and decreased appetite